Vancomycin Taper to Prevent Recurrent Clostridioides Difficile | MicrobiomeTrials← Back to trialsNCT07328971
Vancomycin Taper to Prevent Recurrent Clostridioides Difficile
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-04-24Est. Completion: 2030-06-01
Enrollment target: 500 participants Locations- University of Alberta, Edmonton, Alberta, Canada
- McGill University Health Centre, Montreal, Quebec, Canada
Other microbiome trials you might be interested in
Blood PressureIntraoperative HypotensionPostoperative ComplicationsSurgeryAnesthesia
Rates of major complications and mortality in the first weeks after surgery remain very high: postoperative mortality is…
Hamburg, GermanyCompleted May 25, 2024
DysbiosisClostridium DifficilePet-Human BondingAntibiotic-Associated Colitis
Antimicrobial therapy can lead to disruption of the gut microbiome and infection with Clostridioides difficile, a diseas…
Philadelphia, United States
Est. completion Sep 1, 2026
Ulcerative Colitis (UC)Inflammatory Bowel Disease (IBD)Colitis
This Phase 2b randomized, double-blind, placebo-controlled, multicenter trial will evaluate the efficacy and safety of a…
Izmir, Turkey (Türkiye)Est. completion Dec 30, 2027